Literature DB >> 31978558

Case report on mesangial proliferative glomerulonephritis with multicentric Castleman's disease: Approach to the onset mechanism of immunoglobulin A nephropathy.

Kazunori Karasawa1, Shota Ogura2, Yoei Miyabe2, Kenichi Akiyama2, Kosaku Nitta2, Takahito Moriyama2.   

Abstract

Galactose-deficient immunoglobulin A1 (Gd-IgA1) was recently identified as a critical effector molecule in the pathogenesis of IgA nephropathy (IgAN). Gd-IgA1 is produced by the mucosal immune system. IgAN is thought to develop because of the deposition of a circulating immune-complex containing Gd-IgA1 in the kidney. Multicentric Castleman's disease (MCD) is a rare non-neoplastic lymphoproliferative disorder. As an etiology model, hypercytokinemia, including increased levels of interleukin-6, is the primary pathogenesis of many MCD cases. Here, we present two cases of mesangial proliferative glomerulonephritis with MCD. According to renal biopsy findings, one was diagnosed with non-IgAN and the other with IgAN. Surprisingly, in both cases, Gd-IgA1 was produced by plasma cells in the lymph nodes, suggesting that Gd-IgA1 production alone does not cause IgAN; rather, it may be produced without induction by mucosal immunity. Our findings demonstrate the diversity of the development of IgAN and help to reconsider the onset mechanism of IgAN.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-galactose-deficient IgA1 antibody; Castleman's disease; IgA nephropathy; Mucosal immunity

Year:  2020        PMID: 31978558     DOI: 10.1016/j.clim.2020.108347

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  1 in total

Review 1.  Glomerulonephritis with severe nephrotic syndrome induced by immune complexes composed of galactose-deficient IgA1 in primary Sjögren's syndrome: a case report.

Authors:  Ryo Nishioka; Satoshi Hara; Hiroyuki Kawahara; Kiyoaki Ito; Ichiro Mizushima; Masayoshi Hirata; Michio Nagata; Mitsuhiro Kawano
Journal:  BMC Nephrol       Date:  2021-03-25       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.